Age groups that sustain resurging COVID-19 epidemics in the United States.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Corporate Authors:
      Imperial College COVID-19 Response Team
    • Source:
      Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 0404511 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1095-9203 (Electronic) Linking ISSN: 00368075 NLM ISO Abbreviation: Science Subsets: MEDLINE
    • Publication Information:
      Publication: : Washington, DC : American Association for the Advancement of Science
      Original Publication: New York, N.Y. : [s.n.] 1880-
    • Subject Terms:
      Epidemics*/prevention & control; COVID-19/*epidemiology ; COVID-19/*transmission; Adolescent ; Adult ; Age Factors ; Basic Reproduction Number ; COVID-19/mortality ; COVID-19/prevention & control ; COVID-19 Vaccines ; Cell Phone ; Child ; Child, Preschool ; Communicable Disease Control ; Humans ; Infant ; Middle Aged ; Models, Theoretical ; Pandemics/prevention & control ; Schools ; United States/epidemiology ; Young Adult
    • Abstract:
      After initial declines, in mid-2020 a resurgence in transmission of novel coronavirus disease (COVID-19) occurred in the United States and Europe. As efforts to control COVID-19 disease are reintensified, understanding the age demographics driving transmission and how these affect the loosening of interventions is crucial. We analyze aggregated, age-specific mobility trends from more than 10 million individuals in the United States and link these mechanistically to age-specific COVID-19 mortality data. We estimate that as of October 2020, individuals aged 20 to 49 are the only age groups sustaining resurgent SARS-CoV-2 transmission with reproduction numbers well above one and that at least 65 of 100 COVID-19 infections originate from individuals aged 20 to 49 in the United States. Targeting interventions-including transmission-blocking vaccines-to adults aged 20 to 49 is an important consideration in halting resurgent epidemics and preventing COVID-19-attributable deaths.
      (Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.)
    • References:
      MMWR Morb Mortal Wkly Rep. 2020 Sep 11;69(36):1258-1264. (PMID: 32915165)
      Nature. 2021 Jan;589(7840):82-87. (PMID: 33171481)
      Arch Dis Child. 2021 Jul;106(7):680-686. (PMID: 33172887)
      Science. 2021 Mar 26;371(6536):. (PMID: 33531384)
      JAMA Intern Med. 2020 Jul 21;:. (PMID: 32692365)
      MMWR Morb Mortal Wkly Rep. 2020 Oct 02;69(39):1404-1409. (PMID: 33001872)
      Am J Epidemiol. 2013 Nov 1;178(9):1505-12. (PMID: 24043437)
      Clin Infect Dis. 2020 Nov 19;71(16):2027-2034. (PMID: 32221519)
      Epidemiology. 2019 Sep;30(5):723-736. (PMID: 31274572)
      Nat Commun. 2021 Feb 9;12(1):893. (PMID: 33563992)
      Philos Trans R Soc Lond B Biol Sci. 2004 Jul 29;359(1447):1091-105. (PMID: 15306395)
      Lancet Infect Dis. 2020 Aug;20(8):911-919. (PMID: 32353347)
      BMC Med. 2020 May 7;18(1):124. (PMID: 32375776)
      Clin Infect Dis. 2020 Jul 28;71(15):778-785. (PMID: 32198501)
      N Engl J Med. 2020 Jul 23;383(4):303-305. (PMID: 32412711)
      Ann Appl Stat. 2012 Mar;6(1):1-26. (PMID: 22639701)
      Nature. 2020 Aug;584(7820):257-261. (PMID: 32512579)
      Science. 2020 Jun 26;368(6498):1481-1486. (PMID: 32350060)
      N Engl J Med. 2020 Sep 3;383(10):981-985. (PMID: 32726550)
      Nat Commun. 2021 Jan 12;12(1):323. (PMID: 33436609)
      Lancet Infect Dis. 2020 Jun;20(6):669-677. (PMID: 32240634)
      Nat Commun. 2021 May 10;12(1):2609. (PMID: 33972512)
      Nat Med. 2021 Jan;27(1):78-85. (PMID: 33184509)
      J Infect Dis. 2021 Feb 13;223(3):362-369. (PMID: 33119738)
      Ann Epidemiol. 2020 Aug;48:23-29.e4. (PMID: 32648546)
      BMC Infect Dis. 2014 Mar 10;14:136. (PMID: 24612900)
      JAMA Pediatr. 2021 Feb 1;175(2):143-156. (PMID: 32975552)
      Lancet Infect Dis. 2020 May;20(5):533-534. (PMID: 32087114)
      Sci Adv. 2020 Dec 4;6(49):. (PMID: 33158911)
      Epidemics. 2016 Jun;15:38-55. (PMID: 27266848)
      PLoS Comput Biol. 2021 Jul 26;17(7):e1009098. (PMID: 34310590)
      Lancet Public Health. 2020 Jul;5(7):e375-e385. (PMID: 32502389)
      J Travel Med. 2020 Mar 13;27(2):. (PMID: 32052846)
      Eur J Epidemiol. 2020 Dec;35(12):1123-1138. (PMID: 33289900)
      Nat Med. 2021 Jan;27(1):94-105. (PMID: 33097835)
      Wellcome Open Res. 2020 Apr 28;5:81. (PMID: 32500100)
      MMWR Morb Mortal Wkly Rep. 2020 Oct 23;69(42):1522-1527. (PMID: 33090978)
      PLoS One. 2015 Jul 20;10(7):e0133630. (PMID: 26192322)
      Lancet. 2020 Jun 27;395(10242):1973-1987. (PMID: 32497510)
      J Stat Softw. 2017;76:. (PMID: 36568334)
      Lancet Infect Dis. 2020 Oct;20(10):1141-1150. (PMID: 32562601)
      Nat Med. 2020 Aug;26(8):1205-1211. (PMID: 32546824)
      Public Health. 2020 Oct;187:15-18. (PMID: 32889227)
      Nature. 2020 Aug;584(7821):425-429. (PMID: 32604404)
      PLoS Med. 2008 Mar 25;5(3):e74. (PMID: 18366252)
    • Grant Information:
      United Kingdom WT_ Wellcome Trust; MC_PC_19012 United Kingdom MRC_ Medical Research Council; MR/R015600/1 United Kingdom MRC_ Medical Research Council
    • Accession Number:
      0 (COVID-19 Vaccines)
    • Publication Date:
      Date Created: 20210203 Date Completed: 20210412 Latest Revision: 20240216
    • Publication Date:
      20240216
    • Accession Number:
      PMC8101272
    • Accession Number:
      10.1126/science.abe8372
    • Accession Number:
      33531384